25 August 2016Big Pharma

Video interview: Hogan Lovells discusses implications of Brexit on SPCs

In an exclusive interview with LSIPR, Stephen Bennett, partner at Hogan Lovells, talks about the implications of Brexit with a focus on supplementary protection certificates (SPCs).

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

A clearer picture for SPCs?

8 October 2015 The CJEU’s decision on how an SPC term is to be determined is likely to be welcomed by applicants and owners, but the court has left them to work out how to apply the ruling, say Natalia Wegner-Cribbs and Daniel Wise of Carpmaels & Ransford.

Biotechnology

CJEU adviser to give opinion on SPC term

9 September 2015 An adviser at Europe’s highest court is expected to issue an opinion on whether the term of a supplementary protection certificate begins once it is authorised or when the applicant has been notified about it.

More on this story

A clearer picture for SPCs?

8 October 2015 The CJEU’s decision on how an SPC term is to be determined is likely to be welcomed by applicants and owners, but the court has left them to work out how to apply the ruling, say Natalia Wegner-Cribbs and Daniel Wise of Carpmaels & Ransford.

Biotechnology

CJEU adviser to give opinion on SPC term

9 September 2015 An adviser at Europe’s highest court is expected to issue an opinion on whether the term of a supplementary protection certificate begins once it is authorised or when the applicant has been notified about it.

More on this story

A clearer picture for SPCs?

8 October 2015 The CJEU’s decision on how an SPC term is to be determined is likely to be welcomed by applicants and owners, but the court has left them to work out how to apply the ruling, say Natalia Wegner-Cribbs and Daniel Wise of Carpmaels & Ransford.

Biotechnology

CJEU adviser to give opinion on SPC term

9 September 2015 An adviser at Europe’s highest court is expected to issue an opinion on whether the term of a supplementary protection certificate begins once it is authorised or when the applicant has been notified about it.

More features

Fed Circ orders Teva to delist five patents from Orange Book

Sarepta wins $115M in patent dispute over muscular dystrophy drug

Novartis shields eye-drop patent at European Patent Office

CREATES Act unfairly tips the scales to generics

LSPN launches its first-ever US awards to celebrate life sciences leaders

Pharma giants seek closure on COVID-19 vaccine rows

How Inhibrx defended a $450m damages suit

Foley & Lardner adds litigation and transaction expert in New York